(19)
(11) EP 2 908 800 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.04.2022 Bulletin 2022/16

(45) Mention of the grant of the patent:
16.02.2022 Bulletin 2022/07

(21) Application number: 13777258.8

(22) Date of filing: 10.10.2013
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61K 47/69(2017.01)
 A61K 47/64(2017.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0085; A61K 47/6907; A61K 47/6425
(86) International application number:
PCT/EP2013/071178
(87) International publication number:
WO 2014/057043 (17.04.2014 Gazette 2014/16)

(54)

COMPOSITION AND DELIVERY VEHICLE FOR ACTIVE AGENTS AND METHODS THEREFOR

ZUSAMMENSETZUNG UND FREISETZUNGSVEHIKEL FÜR WIRKSTOFFE SOWIE VERFAHREN DAFÜR

COMPOSITION ET VÉHICULE DE DÉLIVRANCE POUR AGENTS ACTIFS ET PROCÉDÉS ASSOCIÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 12.10.2012 US 201213650193

(43) Date of publication of application:
26.08.2015 Bulletin 2015/35

(73) Proprietors:
  • Steinfeld, Robert
    8708 Männedorf (CH)
  • Allorphan UG
    37075 Göttingen (DE)

(72) Inventors:
  • STEINFELD, Robert
    37077 Göttingen (DE)
  • GRAPP, Marcel
    37083 Göttingen (DE)

(74) Representative: Kröncke, Rolf et al
Gramm, Lins & Partner Patent- und Rechtsanwälte PartGmbB Freundallee 13 a
30173 Hannover
30173 Hannover (DE)


(56) References cited: : 
EP-A1- 2 425 817
WO-A1-2011/097480
 WO-A1-2010/143193
   
  • GUNTER MÜLLER: "Microvesicles/exosomes as potential novel biomarkers of metabolic diseases", DIABETES, METABOLIC SYNDROME AND OBESITY: TARGETS AND THERAPY, 1 August 2012 (2012-08-01), page 247, XP55089998, DOI: 10.2147/DMSO.S32923
  • ROBERT STEINFELD ET AL: "Folate Receptor Alpha Defect Causes Cerebral Folate Transport Deficiency: A Treatable Neurodegenerative Disorder Associated with Disturbed Myelin Metabolism", THE AMERICAN JOURNAL OF HUMAN GENETICS, vol. 85, no. 3, 1 September 2009 (2009-09-01), pages 354-363, XP55090002, ISSN: 0002-9297, DOI: 10.1016/j.ajhg.2009.08.005
  • Todd A Patrick ET AL: "Folate receptors as potential therapeutic targets in choroid plexus tumors of SV40 transgenic mice", Journal of Neuro-Oncology, 1 April 1997 (1997-04-01), pages 111-123, XP55090006, Boston DOI: 10.1023/A:1005713115147 Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pubmed/912 0540-USe of folate receptors as potential therapeutic targets in hte brain.
  • LYDIA ALVAREZ-ERVITI ET AL: "Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes", NATURE BIOTECHNOLOGY, vol. 29, no. 4, 20 March 2011 (2011-03-20) , pages 341-345, XP55089953, ISSN: 1087-0156, DOI: 10.1038/nbt.1807
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).